Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Income from Continuing Operations of 55594000.0 for Q1 2026, down 12.27% year-over-year from 63369635.19 in Q1 2025, and down 17.03% quarter-over-quarter from 47505000.0 in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Income from Continuing Operations for 11 consecutive years, with 55594000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 12.27% year-over-year to 55594000.0; the TTM figure through Mar 2026 stood at 202598000.0 (down 20.04% YoY), while the FY2025 annual figure was 196539000.0, up 24.58% from the prior year.
- Income from Continuing Operations eased to 55594000.0 in Q1 2026 per RYTM's latest filing, from 47505000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 32282000.0 in Q2 2024 and bottomed at 141372000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 51972058.82 across 5 years, with a median of 46703000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 226.48% — and 2025, when it jumped 64.97%.
- Rhythm Pharmaceuticals' Income from Continuing Operations stood at 42493000.0 in 2022, then rose by 2.02% to 41633000.0 in 2023, then dropped by 4.07% to 43328000.0 in 2024, then declined by 9.64% to 47505000.0 in 2025, then retreated by 17.03% to 55594000.0 in 2026.
- Business Quant data shows RYTM's Income from Continuing Operations at 55594000.0 in Q1 2026, 47505000.0 in Q4 2025, and 52904000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -49.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.30 Mn |
| Mar 31, 2026 | -55.59 Mn |
| Dec 31, 2025 | -47.51 Mn |
| Sep 30, 2025 | -52.90 Mn |
| Jun 30, 2025 | -46.60 Mn |
| Mar 31, 2025 | -49.52 Mn |
| Dec 31, 2024 | -43.33 Mn |
| Sep 30, 2024 | -43.64 Mn |
| Jun 30, 2024 | -32.28 Mn |
| Mar 31, 2024 | -141.37 Mn |
| Dec 31, 2023 | -41.63 Mn |
| Sep 30, 2023 | -44.16 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -47.42 Mn |
| Mar 31, 2022 | -55.33 Mn |
| Dec 31, 2021 | -54.07 Mn |
| Sep 30, 2021 | -38.32 Mn |